Navigation Links
NanoPowers Raises CHF 5 Million ($4.5 Million) in Series A Financing to Support Development of Breakthrough Urinary Incontinence Device
Date:6/1/2010

LAUSANNE, Switzerland, June 1, 2010 /PRNewswire/ -- NanoPowers SA, a medical device company that leverages its unique artificial muscle technology to restore or improve muscle function, today announced the closing of a CHF 5 million ($4.5 million) series A financing. The financing round was led by Novartis Venture Funds (NVF). Also participating in the financing were Initiative Capital Romandie (ICR) and Gran Plasa SA. Novartis Venture Funds were also seed investors in the company.

Martin Horst, PhD, chief executive officer, said: "We are very pleased with the ongoing support of the Novartis Venture Funds, and welcome ICR and Gran Plasa to our investor base. We will use the proceeds from the financing to finalize the development of our lead product ARTUS, a breakthrough artificial urinary sphincter, and initiate the first clinical studies. ARTUS addresses a huge unmet medical need, and is the first device of its kind that also lends itself to be easily implanted in women, who are by far the most affected by severe incontinences. Incontinence constitutes a devastating disability, affecting self-confidence and self image, and often leads to social isolation."

Florent Gros, Managing Director of the Novartis Venture Funds, said: "We are excited to support NanoPowers' development of their breakthrough technology applied to artificial sphincters. Incontinence is one of the largest untapped markets in the medical device industry, while demographic changes in western countries are significantly increasing the incidence of incontinences. We believe that ARTUS has the potential to significantly improve patients' quality of live, while substantially reducing treatment c
'/>"/>

SOURCE NanoPowers SA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Curexo Technology Corporation Raises $13.2 Million
2. Cardinal Health Raises Quarterly Dividend By 11 Percent
3. IMPLANET Raises Additional EUR 8 Million (USD 11 Million) to Fuel Deployment
4. Intercept Pharmaceuticals Raises $25 Million Series B Financing
5. The Oclaro Next-Generation Orion Fiber-Coupled Diode Laser Raises the Bar for Performance, Cost and Reliability for Solid State Lasers
6. Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round
7. Apnex Medical, Inc. Raises Additional $14 Million
8. Cambridge-based Ligon Discovery Raises $1M in Seed Funding
9. FREE Drug Discount Card Saves Money on Prescriptions and Raises Funds for Americas Disabled Veterans
10. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
11. NxStage(R) Reports Third Quarter 2009 Financial Results and Raises Revenue Guidance for Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... N.J. , July 29, 2014 Regado ... company focused on the Phase 3 clinical development of ... controllable antithrombotic drug system, today announced that it will ... Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT to ... highlights. Interested participants and investors may access ...
(Date:7/29/2014)... 29, 2014  EnteroMedics Inc. (NASDAQ: ETRM ... to treat obesity, metabolic diseases and other gastrointestinal disorders, ... on Thursday, August 7, 2014 at 11:00 AM Eastern ... ended June 30, 2014 and to provide a business ... second quarter conference call may be accessed by dialing ...
(Date:7/29/2014)... (NYSE: CVD ) today reported results for ... was $639 million, representing 8.0% growth from the second ... reported earnings of $0.29 per diluted share in the ... diluted share of $0.95, up 21.5% over the second ... charges totaling $52.6 million, or $0.61 per share, and ...
Breaking Medicine Technology:Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24
(Date:7/29/2014)... SC (PRWEB) July 29, 2014 During his ... L. Bruce, DMD & Associates, has had a steady stream ... about dentistry. These students have now gone on to dental ... practices, proving that the shadowing program helps college students find ... Dr. Bruce has given them the chance to see a ...
(Date:7/29/2014)... kidney transplants receive steady follow-up care, the living ... make follow-up care more accessible, UC San Francisco ... to launch the first program in the country ... to living kidney donors. , UCSF will provide ... than 4,500 Walgreens pharmacies and Healthcare Clinic at ...
(Date:7/29/2014)... app that helps headache sufferers to record the severity ... part of a Griffith research study. , A new ... looks at coping with their triggers and is being ... Behaviorial Basis of Health program. , He has developed ... the triggers of their headaches called Learning to Cope ...
(Date:7/29/2014)... Bret Busacker , a partner in ... been appointed to the Board of Directors for the ... an experienced business attorney with a focus on employee ... a wide spectrum of topics regarding equity and incentive ... concerns. His clients include public and private businesses, governmental ...
(Date:7/29/2014)... 29, 2014 Child abuse law firm Steinger, ... this week. The scholarship will help future lawyers who want ... families. , Steinger, Iscoe and Greene lawyers work continuously to ... attorneys to do the same. More than 6 million children ... the nonprofit Childhelp (retrieved 7/22/2014). , “This is ...
Breaking Medicine News(10 mins):Health News:Arthur Bruce Dental Helps College Students 2Health News:Caring for donors 2Health News:Caring for donors 3Health News:Holland & Hart Partner Brett Busacker Appointed to Board of Directors for American Red Cross of Greater Idaho 2Health News:Steinger, Iscoe & Greene Offers Child Advocate Scholarship 2
... ... , ... October 6, 2009 -- KelseyCare Advantage , a Houston-based Medicare Advantage plan serving ... Galveston on the Mainland, recently reported its Healthcare Effectiveness Data and Information Set (HEDIS) ...
... other dangers, but behavioral effects remain unclear, , TUESDAY, ... study to suggest an association between the plastics chemical ... report that BPA may affect the behavior of little ... displayed more "externalizing" behaviors, such as aggression and hyperactivity, ...
... SHANGHAI, China, Oct. 6 /PRNewswire-Asia-FirstCall/ -- ... leading Chinese firm,specializing in the manufacture, research, development, marketing ... team will attend the 2009 ROTH China Conference held ... The date, time and location of China-Biotics, presentation at ...
... found in red grapes, has been shown to improve ... little has been known about how these beneficial changes ... for publication in Endocrinology , a journal of ... key role in mediating resveratrol,s anti-diabetic actions, potentially paving ...
... ... Leading health and technology experts gathered recently at ... Health Technology SummitSM to explore advanced medical technologies being used to ... featured presentations was "Artificial Heart--Past, Current and Future," by Alexander Medvedev, ...
... ... Web Designs) is building and giving away 250 Free websites to the first ... so they have angered rivals and received a number of malicious phone calls ... they withdraw their offer to build these 250 free websites for small, local ...
Cached Medicine News:Health News:Local Medicare Advantage Plan Scores High on Diabetic Care and Blood Pressure Control 2Health News: Plastics Chemical Tied to Aggression in Young Girls 2Health News: Plastics Chemical Tied to Aggression in Young Girls 3Health News:China-Biotics, Inc. to Attend 2009 ROTH China Conference 2Health News:Future diabetes treatment may use resveratrol to target the brain 2Health News:Terumo Heart, Inc.'s DuraHeart™ Left-Ventricular Assist System Featured at Future of Health Technology Summit 2Health News:Terumo Heart, Inc.'s DuraHeart™ Left-Ventricular Assist System Featured at Future of Health Technology Summit 3Health News:SEO Consultant Top Rank Web Designs Gives Away 250 Free Websites 2Health News:SEO Consultant Top Rank Web Designs Gives Away 250 Free Websites 3Health News:SEO Consultant Top Rank Web Designs Gives Away 250 Free Websites 4
The DePuy ACE 8.0mm Cannulated Cancellous Screw incorporates TiMAX to provide superior strength, fatigue resistance and a lower modulus of elasticity when compared to similar stainless steel devices....
Smith & Nephew offers a wide variety of cannulated screw products. Most screw sizes are available in both partially threaded and fully threaded versions. , ,All systems optimize implant strength with...
Biomet® Arthrodesis Nail indications include: , Failed external fixation , Aseptic failed total knee arthroplasty , Periarticular fractures where repair is not possible , Limb salvage in tumor...
... Retrograde Humeral Nail enables fixation of humeral ... that may be associated with antegrade nailing. ... and distal interlocking using a nail-mounted targeting ... interlocking with the patient in the prone ...
Medicine Products: